Latest Health News

Vectus Biosystems has reported a striking turnaround with a $1.56 million profit for the 2026 financial year, reversing a prior year loss and improving its balance sheet significantly.

RemSense Technologies reported a 27% revenue decline in FY2026 to $2.49 million due to project timing and economic uncertainty but secured major Tier-1 contracts and raised $1.21 million to fund technology development.

KKR Credit Income Fund has released the audited financial statements for its core investments as of December 31, 2025, revealing mixed returns and ongoing portfolio adjustments across multiple funds.

Nuchev has inked a consignment-based distribution deal to launch the Kuci women’s health probiotic range nationally through Chemist Warehouse, marking a strategic expansion into women’s health.

Bio-Gene Technology narrowed its loss to $2.33 million in FY26 while progressing key toxicity studies for Flavocide and securing a commercial foothold for Qcide in Japan. The company bolstered its balance sheet with a $3.275 million capital raise to fund ongoing development and production scale-up.

Berkeley Energia reported a $8.7 million net loss for FY2026 while pushing forward with its Salamanca uranium project and maiden critical minerals resource at Conchas. The company continues a $1.25 billion ICSID arbitration claim against Spain over permitting delays.

HITIQ Limited posted a 21% drop in revenue to $1.59 million and reduced its net loss by 15% to $6.1 million for FY26, advancing commercialisation of its concussion management platform PROTEQT™ despite ongoing funding pressures and regulatory hurdles.

4DMedical’s CT:VQ™ lung imaging technology secured FDA clearance and CMS reimbursement, driving rapid adoption in top US medical centres and expanding its addressable market to $3 billion with new clinical programs and European contracts.

Micro-X Limited lifted revenues by 16% to $15.1 million for FY26 but posted a $9.9 million net loss, narrowing from the prior year. The company advanced key medical imaging milestones and initiated a strategic reset to sharpen commercial focus and reduce costs.

Cobram Estate Olives (ASX:CBO) posted an 11.3% revenue increase to A$268.9 million in FY2026 but swung to a A$4.2 million net loss as costs surged and integration expenses weighed. The company declared a steady fully franked dividend of 4.5 cents per share.

Rivco Australia’s half-year profit plunged 91% to $2.1 million amid a 35% revenue drop, even as the company boosted its leased water portfolio to 80% and maintained a fully franked dividend.

Resonance Health (ASX: RHT) reported a profitable turnaround in FY26, driven by growth across its imaging software, clinical trial services, and site network businesses.